Daridorexant

Overview

Daridorexant is a small molecule active pharmaceutical ingredient (ChEMBL CHEMBL4297590).

API suppliers (2)

Suppliers of Daridorexant evidenced by a US FDA Type II Drug Master File or an EU Certificate of Suitability (CEP). Sources: FDA DMF list, EDQM certification database.

• MOEHS IBERICA SLSpain1 active DMF GMP on record
• ALP PHARM BEIJING CO LTD1 active DMF

Patent & exclusivity (US)

Per the FDA Orange Book (2 approved US products), the latest listed US patent on Daridorexant expires 2 Dec 2034 and exclusivity 30 Sept 2027. Generic API sourcing typically opens up once these lapse.

Chemical identity

IUPAC name

[(2S)-2-(5-chloro-4-methyl-1H-benzimidazol-2-yl)-2-methylpyrrolidin-1-yl]-[5-methoxy-2-(triazol-2-yl)phenyl]methanone

Canonical SMILES

CC1=C(C=CC2=C1N=C(N2)[C@@]3(CCCN3C(=O)C4=C(C=CC(=C4)OC)N5N=CC=N5)C)Cl

InChIKey

NBGABHGMJVIVBW-QHCPKHFHSA-N